ATE8790T1 - Aromatische heterocyclische steroidester, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten. - Google Patents

Aromatische heterocyclische steroidester, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten.

Info

Publication number
ATE8790T1
ATE8790T1 AT82100490T AT82100490T ATE8790T1 AT E8790 T1 ATE8790 T1 AT E8790T1 AT 82100490 T AT82100490 T AT 82100490T AT 82100490 T AT82100490 T AT 82100490T AT E8790 T1 ATE8790 T1 AT E8790T1
Authority
AT
Austria
Prior art keywords
aromatic heterocyclic
preparation
pharmaceutical compositions
compositions containing
steroid ester
Prior art date
Application number
AT82100490T
Other languages
German (de)
English (en)
Inventor
Elliot L. Shapiro
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation filed Critical Schering Corporation
Application granted granted Critical
Publication of ATE8790T1 publication Critical patent/ATE8790T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT82100490T 1981-02-02 1982-01-25 Aromatische heterocyclische steroidester, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten. ATE8790T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23076381A 1981-02-02 1981-02-02

Publications (1)

Publication Number Publication Date
ATE8790T1 true ATE8790T1 (de) 1984-08-15

Family

ID=22866476

Family Applications (1)

Application Number Title Priority Date Filing Date
AT82100490T ATE8790T1 (de) 1981-02-02 1982-01-25 Aromatische heterocyclische steroidester, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten.

Country Status (25)

Country Link
US (1) US4472393A (OSRAM)
EP (1) EP0057401B1 (OSRAM)
JP (1) JPS57146800A (OSRAM)
KR (1) KR890000761B1 (OSRAM)
AT (1) ATE8790T1 (OSRAM)
AU (1) AU549102B2 (OSRAM)
BG (1) BG60799B2 (OSRAM)
CA (1) CA1177822A (OSRAM)
CY (1) CY1359A (OSRAM)
DE (1) DE3260474D1 (OSRAM)
DK (1) DK162770C (OSRAM)
FI (1) FI78111C (OSRAM)
HK (1) HK68487A (OSRAM)
HU (1) HU188769B (OSRAM)
IE (1) IE52576B1 (OSRAM)
IL (1) IL64885A (OSRAM)
KE (1) KE3694A (OSRAM)
MX (1) MX9203403A (OSRAM)
NL (1) NL930095I2 (OSRAM)
NO (2) NO157020C (OSRAM)
NZ (1) NZ199600A (OSRAM)
OA (1) OA07116A (OSRAM)
PH (1) PH19733A (OSRAM)
PT (1) PT74357B (OSRAM)
ZA (1) ZA82566B (OSRAM)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5446177A (en) * 1984-12-28 1995-08-29 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
US4686214A (en) * 1985-10-30 1987-08-11 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
US4914090A (en) * 1985-11-01 1990-04-03 Schering Corporation Ophthalmic compositions
IL79661A (en) * 1986-08-08 1991-01-31 Yeda Res & Dev Antiviral composition containing hypericin or pseudohypericin
US4808610A (en) * 1986-10-02 1989-02-28 Schering Corporation Mometasone furoate anti-inflammatory cream composition using hexylene glycol
US4775529A (en) * 1987-05-21 1988-10-04 Schering Corporation Steroid lotion
TW197380B (OSRAM) * 1990-03-02 1993-01-01 Glaxo Group Ltd
SK280968B6 (sk) 1990-03-02 2000-10-09 Glaxo Group Limited Balenie medikamentu na použite v inhalačnom prístroji
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
MX9203396A (es) * 1990-09-10 1992-07-31 Schering Corp Monohidrato de furoato de mometasona, proceso para producirlo y composiciones farmaceuticas.
ZA924164B (en) † 1991-06-10 1993-02-24 Schering Corp Non-chlorofluorocarbon aerosol formulations
HUT67445A (en) 1991-06-10 1995-04-28 Schering Corp Aerosol formulations containing 1,1,1,2-tetrafluorethane
US6127353A (en) * 1991-09-06 2000-10-03 Schering Corporation Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
US5420120A (en) * 1993-12-17 1995-05-30 Alcon Laboratories, Inc. Anti-inflammatory glucocorticoid compounds for topical ophthalmic use
CZ283932B6 (cs) * 1993-12-21 1998-07-15 Schering Corporation Použití mometason furoátu a salicylové kyseliny pro přípravu farmaceutického prostředku pro léčbu psoriasy a farmaceutický prostředek
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
PE44995A1 (es) 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
US5502076A (en) * 1994-03-08 1996-03-26 Hoffmann-La Roche Inc. Dispersing agents for use with hydrofluoroalkane propellants
DE4433374A1 (de) * 1994-09-20 1996-03-21 Hoechst Ag 17-Desoxi-corticosteroid-21-/O/-Carbonsäure- ester, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
US5696105A (en) * 1996-03-14 1997-12-09 Hackler; Walter A. Antifungal nail composition
PT923599E (pt) * 1996-06-28 2002-06-28 Schering Corp Processo para a preparacao de 17-esteres de 9alfa,21-di-halopregnano-11beta,17alfadiol-20-onas
US5886200A (en) * 1996-07-01 1999-03-23 Schering Corporation Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones
US6503537B2 (en) 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
US6495167B2 (en) 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
US6297227B1 (en) 1998-09-10 2001-10-02 Schering Corporation Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
US8722668B2 (en) * 1998-12-23 2014-05-13 Daryl W. Hochman Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders
NZ500555A (en) * 1999-08-02 2000-11-24 Hovione Int Ltd Process for the preparation of mometasone furoate
PT102405A (pt) * 2000-01-20 2001-07-31 Hovione Farmaciencia Sa Processo para a preparacao de mometasona
GB0009605D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Medicaments
GB0009612D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic formulations
GB0009609D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic compositions
GB0015876D0 (en) * 2000-06-28 2000-08-23 Novartis Ag Organic compounds
WO2002011711A2 (en) * 2000-08-04 2002-02-14 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
US6777399B2 (en) * 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6759398B2 (en) * 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
CZ2003353A3 (cs) * 2000-08-05 2003-05-14 Glaxo Group Limited Estery steroidních thiokyselin
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
ES2314052T3 (es) * 2001-04-30 2009-03-16 Glaxo Group Limited Derivados de ester de 17beta-carbotioato de androstano con un grupo ester ciclico en la posicion 17alfa.
WO2002100879A1 (en) * 2001-06-12 2002-12-19 Glaxo Group Limited Novel anti-inflammatory 17.alpha.-heterocyclic-esters of 17.beta.carbothioate androstane derivatives
GB0125259D0 (en) 2001-10-20 2001-12-12 Glaxo Group Ltd Novel compounds
WO2003042229A1 (en) * 2001-11-12 2003-05-22 Glaxo Group Limited Non-aromatic heterocyclic esters of furan-2-one-esters of 17.beta.-carboxyl or 17.beta.-carbothio glucocorticoids
GB0127160D0 (en) * 2001-11-12 2002-01-02 Glaxo Group Ltd Novel compounds
ITMI20020148A1 (it) * 2002-01-29 2003-07-29 Nicox Sa Nuovi corticosteroidi
US20050175545A1 (en) * 2002-02-04 2005-08-11 Keith Biggadike Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
GB0202635D0 (en) * 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
GB0207906D0 (en) 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
JP2006523674A (ja) * 2003-04-18 2006-10-19 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 慢性閉塞性肺疾患（ｃｏｐｄ）のための組合せ治療法
NZ545748A (en) * 2003-08-29 2010-03-26 Ranbaxy Lab Ltd Isoxazoline derivatives as inhibitors of phosphodiesterase type-IV
US20070259874A1 (en) * 2003-11-26 2007-11-08 Palle Venkata P Phosphodiesterase Inhibitors
EP2201936B1 (en) * 2004-01-21 2013-06-19 Merck Sharp & Dohme Corp. Method of treating acute rhinosinusitis
US20080009535A1 (en) * 2004-08-30 2008-01-10 Sarala Balachandran Inhibitors of phosphodiesterase type-IV
US20060211667A1 (en) * 2005-03-21 2006-09-21 Eric Marchewitz Use of pregnane steroid derivatives for enhancing physical performance
GB0507165D0 (en) * 2005-04-08 2005-05-18 Glaxo Group Ltd Novel crystalline pharmaceutical product
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
GB0523653D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
US20070099883A1 (en) * 2005-10-07 2007-05-03 Cheryl Lynn Calis Anhydrous mometasone furoate formulation
BRPI0617673C1 (pt) * 2005-10-19 2012-05-22 Ranbaxy Lab Ltd composições de inibidores de fosfodiesterase do tipo iv
BRPI0617674A2 (pt) 2005-10-19 2011-08-02 Ranbaxy Lab Ltd composições farmacêuticas e seus usos
CN100436473C (zh) * 2005-12-09 2008-11-26 天津药业集团有限公司 糠酸莫美他松中间体21-酯及制法
CN100389121C (zh) * 2005-12-09 2008-05-21 天津药业集团有限公司 糠酸莫美他松中间体21-羟的制备方法
AR059216A1 (es) * 2006-01-27 2008-03-19 Sun Pharmaceutical Ind Ltd 11b-hidroxiandrosta-4-eno-3-onas
GB0615108D0 (en) * 2006-07-28 2006-09-06 Glaxo Group Ltd Novel formulations
US20100029728A1 (en) * 2006-09-22 2010-02-04 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
AU2007298549A1 (en) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-IV
EP2083798A1 (en) * 2006-10-19 2009-08-05 Cipla Limited Pharmaceutical compositions and nasal spray incorporating anhydrous mometasone furoate
EP1958947A1 (en) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type 4
ATE545417T1 (de) * 2007-03-14 2012-03-15 Ranbaxy Lab Ltd Pyrazoloä3,4-büpyridin-derivate als phosphodiesterasehemmer
WO2008111009A1 (en) * 2007-03-14 2008-09-18 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
EP2120868A4 (en) * 2007-04-11 2010-08-25 Perrigo Israel Phamaceuticals LOW-DOSED MOMETASON FORMULATIONS
US20100240621A1 (en) * 2007-09-10 2010-09-23 Glenmark Pharmaceuticals Ltd. Topical pharmaceutical composition for the combination of fusidic acid and a corticosteroid
US20090082318A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched mometasone
US8796248B2 (en) * 2007-10-05 2014-08-05 Nektar Therapeutics Oligomer-corticosteroid conjugates
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
EP2278978B1 (en) 2008-05-28 2015-09-02 ReveraGen BioPharma, Inc. Non-hormonal steroid modulators of nf-kb for treatment of disease
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
KR20170070274A (ko) 2009-05-29 2017-06-21 펄 테라퓨틱스 인코포레이티드 지속형 무스카린 안타고니스트 및 지속형 ｂ₂아드레날린 수용체 아고니스트의 폐 전달용 조성물, 및 연관된 방법 및 시스템
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
JP2013506683A (ja) 2009-10-01 2013-02-28 アプタリス ファーマテク，インコーポレイテッド 経口投与型コルチコステロイド組成物
WO2011093810A2 (en) 2010-01-28 2011-08-04 Bilgic Mahmut Dry powder pharmaceutical composition comprising tiotropium and mometasone
EP2533765A2 (en) 2010-01-29 2012-12-19 Mahmut Bilgic Pharmaceutical compositions comprising formoterol and mometasone
US9198921B2 (en) 2010-04-05 2015-12-01 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-κB for treatment of disease
WO2011136754A1 (en) 2010-04-26 2011-11-03 Mahmut Bilgic A medicament developed for the treatment of respiratory diseases
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
WO2013109207A1 (en) 2012-01-16 2013-07-25 Mahmut Bilgic Dry powder formulations comprising mometasone
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
WO2014007771A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising muscarinic receptor antagonist
US10111957B2 (en) 2012-07-05 2018-10-30 Arven Ilac Snayi ve Ticaret A.S. Inhalation compositions comprising glucose anhydrous
WO2014007770A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising corticosteroid and sorbitol
WO2014007781A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions
US9452139B2 (en) 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
BR112015020443A8 (pt) 2013-03-14 2019-11-12 Novartis Ag formulação em pó para inalação, seus usos e seu processo de preparação, e composição farmacêutica
JP6454323B2 (ja) 2013-03-15 2019-01-16 パール セラピューティクス，インコーポレイテッド 粒子状結晶性材料のコンディショニングのための方法及びシステム
BR112015028964A2 (pt) 2013-05-22 2017-07-25 Pearl Therapeutics Inc composição de suspensão, e, método para tratar uma doença ou um distúrbio pulmonar
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
MX2016012641A (es) 2014-03-27 2016-12-14 Novartis Ag Dispersiones solidas secas en aceite en agua por aspersion para inhalacion de ingredientes farmaceuticos activos.
EP3006453A1 (en) 2014-10-08 2016-04-13 Cosmo Technologies Ltd. 17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors
US10799514B2 (en) 2015-06-29 2020-10-13 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-kappa beta for treatment of disease
CN105481933B (zh) * 2015-12-25 2017-09-19 山东京卫制药有限公司 一种合成糠酸莫米松的方法
CN107266519B (zh) * 2016-04-08 2021-06-29 天津金耀集团有限公司 一种9β，11β-环氧-17α-羟基-16α-甲基-21-氯代-1，4孕甾二烯-3，20-二酮新晶型及其制备方法
CN107266518B (zh) * 2016-04-08 2021-03-30 天津金耀集团有限公司 一种糠酸莫米松晶型及其制备方法
TWI728172B (zh) 2016-08-18 2021-05-21 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
CN107793462A (zh) * 2016-08-30 2018-03-13 天津太平洋制药有限公司 一种丙酸氯倍他索的制备方法
CN107778341A (zh) * 2016-08-30 2018-03-09 天津太平洋制药有限公司 一种哈西奈德的制备方法
CN109206466B (zh) * 2017-06-30 2022-08-09 天津药业研究院股份有限公司 一种甾体21位羟基氯代或溴代方法
CN109206468B (zh) * 2017-06-30 2023-06-27 天津药业研究院股份有限公司 一种糠酸莫米松的制备方法
CN107573398B (zh) * 2017-09-07 2021-02-26 山东泰华生物科技股份有限公司 一种哈西奈德及其衍生物的制备方法
CN108395465B (zh) * 2018-05-10 2019-07-30 浙江仙居仙乐药业有限公司 一种地塞米松环氧水解物的合成方法
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions
MA60223B1 (fr) 2021-07-09 2024-06-28 Astrazeneca Pharmaceuticals Lp Compositions, procédés et systèmes pour l'administration d'un médicament en aérosol
EP4452230A1 (en) 2021-12-20 2024-10-30 Astrazeneca AB Compositions, methods and systems for aerosol drug delivery
EP4566595A1 (en) 2023-12-07 2025-06-11 Bernhard Roth Combination preparation for the treatment of acute and chronic rhinosinusitis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1059906B (de) * 1954-10-05 1959-06-25 Scherico Ltd Verfahren zur Herstellung von 1, 4-Pregnadienen
US3557158A (en) * 1962-01-22 1971-01-19 Upjohn Co 6alpha-fluoro-16-methyl - 4 - pregnene 3,20-diones and intermediates produced in the synthesis thereof
US3422193A (en) * 1966-08-11 1969-01-14 Schering Corp 17-mono esters of corticoids
IT1061787B (it) * 1967-03-01 1983-04-30 Vismara Francesco Spa Miglioramenti relativi alla preparazione di 17 benzoato di betametazone
US3784692A (en) * 1967-06-16 1974-01-08 Warner Lambert Co 17-propionate,21-ester derivatives of 6alpha,9alpha-difluoroprednisolone,compositions and use
GB1253831A (en) * 1968-01-19 1971-11-17 Glaxo Lab Ltd 9alpha,21-DIHALOPREGNANE COMPOUNDS
US3980778A (en) * 1973-10-25 1976-09-14 The Upjohn Company Anti-inflammatory steroid
NL7502252A (nl) * 1974-02-27 1975-08-29 Pierrel Spa Werkwijze voor het bereiden van een geneesmid- del met anti-inflammatoire werking, gevormd ge- neesmiddel verkregen volgens deze werkwijze alsmede werkwijze voor het bereiden van in het geneesmiddel gebruikte nieuwe steroiden.
GB1505701A (en) * 1975-06-14 1978-03-30 Pierrel Spa 2-chloro-6beta-fluoropregnanes
US4221787A (en) * 1978-03-28 1980-09-09 Interx Research Corporation Esteramide prodrugs of anti-inflammatory corticosteroids

Also Published As

Publication number Publication date
MX9203403A (es) 1992-07-01
PH19733A (en) 1986-06-17
IL64885A0 (en) 1982-03-31
EP0057401A1 (en) 1982-08-11
OA07116A (fr) 1984-03-31
AU7991882A (en) 1982-08-12
JPS6360036B2 (OSRAM) 1988-11-22
NZ199600A (en) 1984-09-28
KR830009138A (ko) 1983-12-17
FI820280L (fi) 1982-08-03
KE3694A (en) 1987-03-13
NO1994018I1 (no) 1994-10-07
HK68487A (en) 1987-10-02
NL930095I2 (nl) 1994-12-01
US4472393A (en) 1984-09-18
NO157020C (no) 1988-01-06
IE52576B1 (en) 1987-12-23
IL64885A (en) 1985-05-31
NO157020B (no) 1987-09-28
EP0057401B1 (en) 1984-08-01
CA1177822A (en) 1984-11-13
AU549102B2 (en) 1986-01-16
DK162770C (da) 1992-04-27
JPS57146800A (en) 1982-09-10
DK162770B (da) 1991-12-09
BG60799B2 (bg) 1996-03-29
PT74357B (en) 1984-05-30
IE820207L (en) 1982-08-02
NO820263L (no) 1982-08-03
CY1359A (en) 1987-08-07
DK39082A (da) 1982-08-03
FI78111B (fi) 1989-02-28
NL930095I1 (nl) 1993-10-01
HU188769B (en) 1986-05-28
KR890000761B1 (ko) 1989-04-05
PT74357A (en) 1982-02-01
ZA82566B (en) 1982-12-29
FI78111C (fi) 1989-06-12
DE3260474D1 (en) 1984-09-06

Similar Documents

Publication Publication Date Title
ATE8790T1 (de) Aromatische heterocyclische steroidester, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
FR2514769B1 (fr) Dipropionate de beclomethasone, son procede de preparation et compositions pharmaceutiques le contenant
DE3369508D1 (en) Triphenylimidazolyloxyalcanoic acids and their derivatives, process for their preparation and pharmaceutical compositions containing them
DE19975037I2 (de) 3H-Imidazo-5,1-d-1,2,3,5-tetrazin-4-on-Derivate Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
DE2963572D1 (en) Mercapto-imidazole derivatives, their preparation, mercapto-imidazole derivatives for the treatment of inflammatory diseases and their pharmaceutical compositions
ATE4707T1 (de) Pyridyl- und imidazopyridyloxypropanolamine, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen sie enthaltend.
DE2964774D1 (en) 2,6-dialkoxybenzamides, process for their preparation, compositions and these compounds for use in the treatment of psychotic disordes
ATE489T1 (de) Sila-substituierte 1,4-dihydropyridinderivate, verfahren zu ihrer herstellung, arzneimittel und verfahren zu deren herstellung.
DE3371515D1 (en) Cycloalkyl derivatives of benzisoselenazolones, process for their preparation and pharmaceutical compositions containing them
IL57215A0 (en) Esters of substituted 8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1h-3-benzazepines,process for the preparation thereof and pharmaceutical compositions containing them
PH15720A (en) Hypolipidemic derivatives of 4,5-dihydro-4-oxo-furan-2-carboxylic acid,their pharmaceutical compositions and method of use
IL56442A (en) Solvent vehicle for the parenteral administration of therapeutics containing an adipic acid ester,pharmaceutical compositions comprising said vehicle and their use in the prophylaxis and/or treatment of certain diseases
DE2861570D1 (en) 17 alpha-aryl or 17 alpha-heteroaryl steroids, process for their preparation, their use as medicines and pharmaceutical compositions containing them
GB2009177B (en) Amino-and guanidino -1,2,3,4 - tetrahydro -unaphtoic acid esters process for their preparation and pharmaceutical compositions containing them
IL54041A0 (en) Pharmaceutical compositions for enteral or vaginal application
ATE7144T1 (de) 4,4 dialkyl-4-sila-fettsaeureamide, zwischenprodukte, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
ATE53993T1 (de) 1,4-dihydropyridincarbonsaeure-ester, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ZA80619B (en) New laevorotatory basic derivative of 9,10-ethanoanthracene,process for the manufacture thereof,pharmaceutical compositions containing this compound and their use
ATE27150T1 (de) 2-oxo-1-pyrrolidinessigsaeureester, verfahren zu ihrer herstellung und pharmazeutische zusammenstellungen, die diese enthalten.
ATE18907T1 (de) 3,5-di-tert-butylstyrenderivate, verfahren zu ihrer herstellung und pharmazeutische zusammenstellungen, die sie enthalten.
ATE876T1 (de) Anti-inflammatorische 4,5 -diaryl-2-nitroimidazole, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzung.
ATE3413T1 (de) Neues links-drehendes, basisches derivat des 9,10-aethanoanthracens, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische praeparate.
ZA796513B (en) Substituted 2-phenylamino-imidazolines-(2),having particular therapeutic properties,process for their preparation,and pharmaceutical compositions containing them
ATE4986T1 (de) Cephalosporinderivate, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
ATE4218T1 (de) 3,20-dioxo-4,9-dien-21-hydroxy-steroidderivate, verfahren zu ihrer herstellung, ihre anwendung in arzneimitteln und pharmazeutische zusammensetzungen, die sie enthalten.